Announcements - OBI Pharma 台灣浩鼎

2022.Oct.06

Announcement on behalf of AP Biosciences of the resignation of its institutional director

2022.Oct.05

OBI PHARMA INC. to attend investor conference hosted by MASTERLINK SECURITIES

2022.Oct.04

Announcement of AP Biosciences’ full receipt of cash capital increase in 2022 and the reference date of capital increase

2022.Oct.03

Announcement of the expiration of AP Biosciences’ 2022 cash capital increase call period

2022.Sep.12

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to TFDA

2022.Sep.10

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by US FDA

2022.Aug.31

Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons

2022.Aug.31

Announcement on behalf of AP Biosciences’ call period of 2022 cash capital increase

2022.Aug.12

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA

2022.Aug.11

Announcement of amendment of the Company's 2021 Annual Report

News

Latest News

Events

Latest events